期刊
MOLECULAR PHARMACEUTICS
卷 11, 期 3, 页码 755-765出版社
AMER CHEMICAL SOC
DOI: 10.1021/mp4004699
关键词
CXCR4; liposome; siRNA; breast cancer; lipocalin-2; migration
资金
- NIH [NCI 1DP2CA174495]
- Breast Cancer Research Foundation
Because breast cancer patient survival inversely correlates with metastasis, we engineered vehicles to inhibit both the C-X-C chemokine receptor type 4 (CXCR4) and lipocalin-2 (Lcn2) mediated migratory pathways. pH-responsive liposomes were designed to protect and trigger the release of Lcn2 siRNA. Liposomes were modified with anti-CXCR4 antibodies to target metastatic breast cancer (MBC) cells and block migration along the CXCR4 CXCL12 axis. This synergistic approach coupling the CXCR4 axis blockade with Lcn2 silencing significantly reduced migration in triple-negative human breast cancer cells (88% for MDA-MB-436 and 92% for delivery vehicles engineered to attack multiple migratory pathways may effectively slow progression MDA-MB-231). The results suggested that drug delivery vehicles engineered to attack multiple migratory pathways may effectively slow progression of MBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据